Corbus Pharmaceuticals Holdings, Inc. (CRBP) - 2025 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2025. Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oncology and obesity. The company has no commercial product revenue and relies on equity financing to fund operations. Its primary pipeline assets are CRB-701 (an antibody-drug conjugate for solid tumors) and CRB-913 (an oral small molecule for obesity). The company deprioritized its CRB-601 program in late 2025.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(78.5) million | $(40.2) million |
| Research & Development (R&D) Expense | $70.1 million | $32.2 million |
| General & Administrative (G&A) Expense | $15.2 million | $16.5 million |
| Cash, Cash Equivalents, and Investments | $163.3 million | $149.1 million |
| Accumulated Deficit | $(555.4) million | $(476.9) million |
| Net Cash Used in Operating Activities | $(64.5) million | $(41.8) million |
| Net Cash Provided by Financing Activities | $77.4 million | $166.6 million |
Material Changes vs. Prior Period
- Increased R&D Spend: R&D expenses surged 118% to $70.1 million, driven by the expansion of the CRB-701 Phase 1/2 clinical trial (adding sites and patients) and the completion of the CRB-913 Phase 1a study.
- Capital Raising: The company raised approximately $70.2 million in net proceeds from a public offering in November 2025 and $7.0 million via an Open Market Sale Agreement during the year.
- Debt Repayment: The company fully repaid its loan from K2 HealthVentures LLC in August 2024, resulting in zero interest expense for 2025 compared to $1.9 million in 2024.
- Program Deprioritization: The CRB-601 program was deprioritized in November 2025, though costs for the year remained significant due to prior commitments.
Guidance, Outlook, and Risks
- Clinical Milestones:
- CRB-701: Dose expansion is ongoing. The company expects to meet with the FDA in Q1 2026 to discuss registrational study protocols for Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancer. Fast track designation was received for both indications.
- CRB-913: Phase 1a SAD/MAD study completed in December 2025 with positive safety and early weight loss signals. Phase 1b "CANYON-1" study initiated in December 2025, with completion expected in Summer 2026.
- Liquidity Outlook: Management expects current cash and investments ($163.3 million) to fund operations for at least 12 months from the filing date. However, the company anticipates continued significant losses and will require additional capital to advance clinical programs.
- Key Risks:
- Capital Requirements: Failure to raise additional capital could force delays or discontinuation of clinical trials.
- Regulatory Uncertainty: No assurance that clinical data will support FDA approval or that the FDA will accept data from international trials (e.g., CSPC's Phase 3 in China).
- Third-Party Dependence: Reliance on CSPC for CRB-701 manufacturing and supply, and on CROs for clinical execution.
- Geopolitical Factors: Potential impact of U.S.-China trade relations on the CSPC partnership.
Investor Verification Checklist
- Verify the timeline and specific endpoints for the anticipated Q1 2026 FDA meeting regarding CRB-701.
- Confirm the enrollment rates and safety data for the ongoing CRB-701 dose expansion and the new CRB-913 Phase 1b study.
- Monitor the company's cash burn rate against the $163.3 million cash balance to assess the runway for future financing needs.
- Review the terms of the CSPC license agreement regarding manufacturing obligations and potential geopolitical risks.
- Assess the competitive landscape for Nectin-4 ADCs (e.g., PADCEV) and oral obesity treatments (e.g., GLP-1s) relative to Corbus's emerging data.